Moomoo AI 已提取核心信息
BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies, has announced the offering of 15,000,000 shares of its Class A common stock at $1.00 per share, alongside pre-funded warrants to purchase up to 6,000,000 shares of common stock and warrants to purchase up to 10,500,000 shares of common stock. The pre-funded warrants are exercisable at $0.0001 per share, with a purchase price of $0.9999 each, and are immediately exercisable. The common warrants have an exercise price of $1.50 per share, are also immediately exercisable, and will expire five years from the issuance date. The shares and warrants are being sold together but will be issued separately and are immediately separable upon issuance. ThinkEquity LLC has been engaged as the exclusive...Show More
BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies, has announced the offering of 15,000,000 shares of its Class A common stock at $1.00 per share, alongside pre-funded warrants to purchase up to 6,000,000 shares of common stock and warrants to purchase up to 10,500,000 shares of common stock. The pre-funded warrants are exercisable at $0.0001 per share, with a purchase price of $0.9999 each, and are immediately exercisable. The common warrants have an exercise price of $1.50 per share, are also immediately exercisable, and will expire five years from the issuance date. The shares and warrants are being sold together but will be issued separately and are immediately separable upon issuance. ThinkEquity LLC has been engaged as the exclusive placement agent for the offering. The placement agent will use reasonable best efforts to arrange for the sale of the securities, but is not required to sell any specific number or dollar amount. The offering is expected to close on or about March 6, 2024, subject to customary closing conditions. The date of the prospectus supplement is March 4, 2024.
专注于创新药物疗法开发的临床阶段公司BioVie Inc. 宣布以每股1.00美元的价格发行1500万股A类普通股，同时发行购买最多600万股普通股的预筹认股权证和购买最多1050万股普通股的认股权证。预先注资的认股权证可按每股0.0001美元的价格行使，每份认股权证的收购价为0.9999美元，可立即行使。普通认股权证的行使价为每股1.50美元，也可以立即行使，并将自发行之日起五年内到期。股票和认股权证一起出售，但将分开发行，发行后可立即分离。ThinkEquity LLC已被聘为本次发行的独家配售代理。配售代理人将尽最大努力安排证券的出售，但无需出售任何特定数量或金额的证券。此次发行预计将于2024年3月6日左右结束，但须遵守惯例成交条件。招股说明书补充材料的发布日期为2024年3月4日。
专注于创新药物疗法开发的临床阶段公司BioVie Inc. 宣布以每股1.00美元的价格发行1500万股A类普通股，同时发行购买最多600万股普通股的预筹认股权证和购买最多1050万股普通股的认股权证。预先注资的认股权证可按每股0.0001美元的价格行使，每份认股权证的收购价为0.9999美元，可立即行使。普通认股权证的行使价为每股1.50美元，也可以立即行使，并将自发行之日起五年内到期。股票和认股权证一起出售，但将分开发行，发行后可立即分离。ThinkEquity LLC已被聘为本次发行的独家配售代理。配售代理人将尽最大努力安排证券的出售，但无需出售任何特定数量或金额的证券。此次发行预计将于2024年3月6日左右结束，但须遵守惯例成交条件。招股说明书补充材料的发布日期为2024年3月4日。
有用
没用
